T36.6X2D Poisoning by rifampicins, intentional self-harm, subsequent encounter

Name of the Condition

• Poisoning by rifampicins, intentional self-harm, subsequent encounter

Summary

This condition describes intentional self-harm poisoning by rifampicins during a subsequent encounter. It applies when rifampicin exposure results in harmful effects due to intentional overdose or self-inflicted exposure, and the patient is receiving ongoing care after the initial event. Documentation should specify the intentional self-harm nature of the event and the subsequent encounter context to guide accurate coding.

Causes

Intentional self-harm poisoning may result from deliberate overdose or self-inflicted exposure to rifampicins. This can occur due to suicidal intent, self-harm behaviors, or attempts to manipulate therapeutic outcomes. Adverse effects may stem from idiosyncratic reactions or drug interactions, though the focus here is on intentional exposure.

Risk Factors

• Prior history of mental health conditions or suicidal ideation.
• Access to rifampicins without supervision.
• Substance use disorders increasing self-harm risks.
• Prior episodes of intentional self-harm or overdose.
• Inadequate psychosocial support or crisis intervention.

Symptoms

• Gastrointestinal: Nausea, vomiting, abdominal pain, diarrhea.
• Allergic: Rash, urticaria, or anaphylaxis in severe cases.
• Systemic: Fever, hypotension, hepatotoxicity, or organ dysfunction.
• Neurological: Dizziness, confusion, seizures, or altered mental status.
• Hematologic: Thrombocytopenia, leukopenia, or coagulopathy.

Diagnosis

Evaluation includes patient history of intentional rifampicin exposure, clinical assessment of symptoms, and laboratory testing (e.g., liver function, renal function, drug levels). Imaging or other studies may be used to assess organ damage. Documentation should confirm the intentional self-harm context and subsequent encounter timing.

Treatment Options

Treatment focuses on stabilizing the patient, managing symptoms, and addressing underlying mental health needs. Interventions may include activated charcoal, supportive care, antidotes (if available), and psychiatric evaluation. Long-term care may involve therapy, medication management, and safety planning.

Prognosis and Follow-Up

Prognosis depends on the severity of poisoning, timeliness of treatment, and underlying mental health status. Follow-up includes monitoring for recurrence, addressing psychosocial factors, and coordinating with mental health providers. Regular assessments ensure ongoing stability and adherence to safety plans.

Complications

• Severe hepatotoxicity or liver failure.
• Renal impairment or failure.
• Neurological damage (e.g., seizures, coma).
• Hematologic abnormalities (e.g., bleeding, infection).
• Psychological sequelae (e.g., depression, PTSD).

Lifestyle & Prevention

• Secure storage of rifampicins to prevent access.
• Regular mental health screening and support.
• Education on medication safety and self-harm risks.
• Development of crisis intervention plans.
• Collaboration with healthcare providers for ongoing care.

When to Seek Professional Help

Seek immediate medical attention for symptoms of poisoning (e.g., severe nausea, confusion, organ dysfunction) or if self-harm is suspected. Contact emergency services or a mental health professional for suicidal thoughts or behaviors.

Tips for Medical Coders

Document the intentional self-harm nature of the event and subsequent encounter details clearly. Specify the type of rifampicin involved and any associated complications. Ensure encounter timing (subsequent) and intent (intentional self-harm) are accurately reflected to support correct coding.